These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

628 related items for PubMed ID: 30851347

  • 1. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
    Miyawaki E, Kenmotsu H, Mori K, Harada H, Mitsuya K, Mamesaya N, Kawamura T, Kobayashi H, Nakashima K, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Endo M, Nakasu Y, Gon Y, Takahashi T.
    Int J Radiat Oncol Biol Phys; 2019 Jul 01; 104(3):604-613. PubMed ID: 30851347
    [Abstract] [Full Text] [Related]

  • 2. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, Beal K, Amini A, Patil T, Kavanagh BD, Camidge DR, Braunstein SE, Boreta LC, Balasubramanian SK, Ahluwalia MS, Rana NG, Attia A, Gettinger SN, Contessa JN, Yu JB, Chiang VL.
    J Clin Oncol; 2017 Apr 01; 35(10):1070-1077. PubMed ID: 28113019
    [Abstract] [Full Text] [Related]

  • 3. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
    Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL.
    Int J Radiat Oncol Biol Phys; 2016 Jun 01; 95(2):673-9. PubMed ID: 27034176
    [Abstract] [Full Text] [Related]

  • 4. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    Chen YH, Chen YF, Chen CY, Shih JY, Yu CJ.
    BMC Cancer; 2019 Oct 26; 19(1):1006. PubMed ID: 31655564
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S, Ham JS, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
    Med Oncol; 2016 Aug 26; 33(8):97. PubMed ID: 27447711
    [Abstract] [Full Text] [Related]

  • 7. Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
    Saruwatari K, Ikeda T, Saeki S, Shingu N, Imamura K, Komatu T, Ushijima S, Maruyama H, Kashiwabara K, Tomita Y, Ichiyasu H, Fujii K, Sakagami T.
    Anticancer Res; 2019 Feb 26; 39(2):923-931. PubMed ID: 30711977
    [Abstract] [Full Text] [Related]

  • 8. Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis.
    Hyun DG, Choi CM, Lee DH, Kim SW, Yoon S, Kim WS, Ji W, Lee JC.
    PLoS One; 2020 Feb 26; 15(4):e0231546. PubMed ID: 32298306
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT, Chen JS, Liao WY, Ho CC, Hsu CL, Yang CY, Chen KY, Lee JH, Lin ZZ, Shih JY, Yang JC, Yu CJ.
    Int J Cancer; 2019 Jun 01; 144(11):2887-2896. PubMed ID: 30485437
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant.
    Zhao L, Cai X, Chen D, Ye X, Gao M, Lu L, Su H, Su M, Hou M, Xie C.
    Radiat Oncol; 2019 Dec 31; 15(1):3. PubMed ID: 31892337
    [Abstract] [Full Text] [Related]

  • 12. Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis.
    Zhao Y, Li S, Yang X, Chu L, Wang S, Tong T, Chu X, Yu F, Zeng Y, Guo T, Zhou Y, Zou L, Li Y, Ni J, Zhu Z.
    Int J Cancer; 2022 Apr 15; 150(8):1318-1328. PubMed ID: 34914096
    [Abstract] [Full Text] [Related]

  • 13. The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
    Jung HA, Park S, Lee SH, Ahn JS, Ahn MJ, Sun JM.
    Cancer Res Treat; 2023 Apr 15; 55(2):479-487. PubMed ID: 36596729
    [Abstract] [Full Text] [Related]

  • 14. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.
    Yang WC, Xiao F, Shih JY, Ho CC, Chen YF, Tseng HM, Chen KY, Liao WY, Yu CJ, Yang JC, Kuo SH, Cheng JC, Yang PC, Hsu FM.
    Radiother Oncol; 2018 Feb 15; 126(2):368-374. PubMed ID: 29111173
    [Abstract] [Full Text] [Related]

  • 15. Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC).
    Zhu Q, Sun Y, Cui Y, Ye K, Yang C, Yang D, Ma J, Liu X, Yu J, Ge H.
    Oncotarget; 2017 Feb 21; 8(8):13304-13311. PubMed ID: 28076323
    [Abstract] [Full Text] [Related]

  • 16. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.
    Cai L, Zhu JF, Zhang XW, Lin SX, Su XD, Lin P, Chen K, Zhang LJ.
    J Neurooncol; 2014 Nov 21; 120(2):423-30. PubMed ID: 25098700
    [Abstract] [Full Text] [Related]

  • 17. A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.
    Yang H, He D, Wang F, Deng Q, Xie Z.
    Clin Exp Metastasis; 2020 Jun 21; 37(3):391-399. PubMed ID: 32356218
    [Abstract] [Full Text] [Related]

  • 18. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC, Lim CK, Chang LY, Chen KY, Shih JY, Yu CJ.
    Eur J Cancer; 2019 Sep 21; 119():77-86. PubMed ID: 31425965
    [Abstract] [Full Text] [Related]

  • 19. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients.
    Yomo S, Oda K.
    Lung Cancer; 2018 May 21; 119():120-126. PubMed ID: 29656746
    [Abstract] [Full Text] [Related]

  • 20. Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses.
    Kuan AS, Chiang CL, Wu HM, Yang HC, Chen CJ, Lin CJ, Guo WY, Pan DH, Chung WY, Lee CC.
    J Neurooncol; 2023 Sep 21; 164(3):729-739. PubMed ID: 37721662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.